Glycogen phosphorylase inhibitors as potential drugs for the treatment of type 2 diabetes

被引：0
|
作者：
Ganotidisi, Minas H. [1 ]
Elemes, Yiannis [1 ]
Alexopoulos, Charalampos [1 ]
Sakarellos, Constantinos [1 ]
Kosmopoulou, Magda N. [1 ]
Chrysina, Evangelia D. [1 ]
Leonidas, Demetres D. [1 ]
Oikonomakos, Nikos G. [1 ]
机构：
[1] Univ Ioannina, Dept Chem, GR-45110 Ioannina, Greece
来源：
Peptides 2004, Proceedings: BRIDGES BETWEEN DISCIPLINES | 2005年
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：844 / 845
页数：2
相关论文
共 50 条
  • [31] Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups
    Sparks, Steven M.
    Banker, Pierette
    Bickett, David M.
    Carter, H. Luke
    Clancy, Daphne C.
    Dickerson, Scott H.
    Dwornik, Kate A.
    Garrido, Dulce M.
    Golden, Pamela L.
    Nolte, Robert T.
    Peat, Andrew J.
    Sheckler, Lauren R.
    Tavares, Francis X.
    Thomson, Stephen A.
    Wang, Liping
    Weiel, James E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (03) : 976 - 980
  • [32] Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
    Drucker, DJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (01) : 87 - 100
  • [33] C-(β-D-glucopyranosyl) heterocycles as potential glycogen phosphorylase inhibitors
    Hadady, Z
    Tóth, M
    Somsák, L
    ARKIVOC, 2004, : 140 - 149
  • [34] Anomeric Spironucleosides of β-d-Glucopyranosyl Uracil as Potential Inhibitors of Glycogen Phosphorylase
    Stathi, Aggeliki
    Mamais, Michael
    Chrysina, Evangelia D.
    Gimisis, Thanasis
    MOLECULES, 2019, 24 (12):
  • [35] Discovery of novel heterocyclic derivatives as potential glycogen phosphorylase inhibitors with a cardioprotective effect
    Yan, Zhiwei
    Li, Shuai
    Wang, Youde
    Li, Jing
    Ma, Can
    Guo, Yachun
    Zhang, Liying
    BIOORGANIC CHEMISTRY, 2022, 129
  • [36] New drugs for the treatment of type 2 diabetes
    Chowdhury, Tahseen A.
    Hossain, Belayet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2007, 68 (04) : 178 - 183
  • [37] New drugs for treatment of diabetes type 2
    Gallego, VP
    Pardos, CL
    Mayor, MJD
    Martín, AV
    REVISTA CLINICA ESPANOLA, 2000, 200 (03): : 151 - 156
  • [38] THE DESIGN OF POTENTIAL ANTIDIABETIC DRUGS - EXPERIMENTAL INVESTIGATION OF A NUMBER OF BETA-D-GLUCOSE ANALOG INHIBITORS OF GLYCOGEN-PHOSPHORYLASE
    OIKONOMAKOS, NG
    KONTOU, M
    ZOGRAPHOS, SE
    TSITOURA, HS
    JOHNSON, LN
    WATSON, KA
    MITCHELL, EP
    FLEET, GWJ
    SON, JC
    BICHARD, CJF
    LEONIDAS, DD
    ACHARYA, KR
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1994, 19 (03) : 185 - 192
  • [39] Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy
    Thomson, Stephen A.
    Banker, Pierette
    Bickett, D. Mark
    Boucheron, Joyce A.
    Carter, H. Luke
    Clancy, Daphne C.
    Cooper, Joel P.
    Dickerson, Scott H.
    Garrido, Dulce M.
    Nolte, Robert T.
    Peat, Andrew J.
    Sheckler, Lauren R.
    Sparks, Steven M.
    Tavares, Francis X.
    Wang, Liping
    Wang, Tony Y.
    Weiel, James E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) : 1177 - 1182
  • [40] Glucopyranose spirohydantoins: Specific inhibitors of glycogen phosphorylase
    delaFuente, C
    Krulle, TM
    Watson, KA
    Gregoriou, M
    Johnson, LN
    Tsitsanou, KE
    Zographos, SE
    Oikonomakos, NG
    Fleet, GWJ
    SYNLETT, 1997, (05) : 485 - &
12345